Objective: To develop evidence-based guidelines for preventing or treating neonatal pain and its adverse consequences. Compared with older children and adults, neonates are more sensitive to pain and vulnerable to its longterm effects. Despite the clinical importance of neonatal pain, current medical practices continue to expose infants to repetitive, acute, or prolonged pain. Design: Experts representing several different countries, professional disciplines, and practice settings used systematic reviews, data synthesis, and open discussion to develop a consensus on clinical practices that were supported by published evidence or were commonly used, the latter based on extrapolation of evidence from older age groups. A practical format was used to describe the analgesic management for specific invasive procedures and for ongoing pain in neonates.
N EWBORNS routinely experience pain associated with invasive procedures such as blood sampling, immunization, vitamin K injection, or circumcision. The sick or preterm infant may experience repetitive or prolonged pain resulting from many diagnostic, surgical, or therapeutic procedures. [1] [2] [3] [4] Multiple lines of evidence suggest an increased sensitivity to pain in neonates compared with older age groups. 5, 6 This pain sensitivity is further accentuated in preterm neonates, and may not be clinically evident. [5] [6] [7] [8] Critically ill and preterm neonates do not mount vigorous behavioral responses to pain, and therefore require particularly detailed assessment. [6] [7] [8] The pain modulation systems that operate in older children and adults do not appear to be fully functional in newborns [9] [10] [11] or may function only during maternal contact in healthy newborns. 12 Even the most immature preterm neonates mount increasing re-sponses to the pain caused by mild, moderate, or highly invasive procedures, and the magnitude of their responses increase with postnatal age. 6, 7, 13 Compared with older children, neonates exhibit greater hormonal, metabolic, and cardiovascular responses to surgical operations, and may require relatively higher doses of anesthetics and analgesics for adequate pain control. 5, [14] [15] [16] [17] The metabolism and clearance rates of most analgesic agents in preterm neonates are slower than in term neonates, but increase rapidly with age. 18, 19 Management of pain in the newborn is hampered by the lack of awareness among health care professionals that the neonate is capable of experiencing pain, and by fears about the adverse effects associated with analgesic use. Current evidence supports the general principles listed in Table 1 for the routine management of neonates using safe and effective environmental, behavioral, and pharmacological interventions for relieving pain and for preventing its adverse consequences. 20 
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RESULTS

EVIDENCE-BASED GUIDELINES FOR THE MANAGEMENT OF NEONATAL PAIN
Recognition of the Sources of Pain
Some of the painful procedures commonly performed on neonates in the neonatal intensive care unit (NICU) include heel lancing, venipuncture, venous or arterial cath-eter insertion, chest tube placement, tracheal intubation or suctioning, lumbar puncture, and subcutaneous or intramuscular injections (see Table 2 for additional procedures). [1] [2] [3] [4] Other sources of pain may include areas of inflammation and hyperalgesia around previous tissue injury, postoperative pain, localized infection or inflammation, and skin burns or abrasions caused by transcutaneous probes, monitoring leads, or topical agents.
METHODS
These guidelines were developed from 2 consensus development meetings (in April 1998 and August 1999). A detailed search of the published literature on neonatal pain was conducted to identify the experts who were invited to these meetings. Databases searched were MEDLINE, Embase, and PubMed using the following terms:pain,nociception,stress,infant-newborn,andinfantpremature. Faculty members were selected by the chairman (K.J.S.A.) based on their expertise in specific topics related to neonatal pain, coupled with a concerted effort to include professionals trained in different disciplines and representing different countries and distinct practice settings (eg, children's hospitals, general hospitals, office practices). The disciplines represented were pediatrics, neonatology, child psychology, anesthesiology, neuroscience, endocrinology, neonatal nursing, pharmacy/pharmacology, rehabilitation medicine, critical care medicine, rheumatology/immunology, and others. At the time of these meetings, faculty members were affiliated to academic institutions in Australia, Brazil, Canada, Denmark, France, Germany, Israel, Italy, Poland, Sweden, Switzerland, the Netherlands, United Kingdom, and the United States. Faculty members performed a systematic review of the published literature on their specific topic, critically evaluated the quality of published data, and synthesized these findings. Data from all relevant studies were presented at these meetings and were discussed by the experts present. Other faculty members were encouraged to present additional data and ample time was allowed for detailed discussion. Guidelines were developed after reaching a consensus on the clinical practices that were prevalent in most countries. As such, these guidelines were based on a combination of published evidence (from randomized controlled trials, systematic reviews, or meta-analyses of trials) and its critical evaluation by the faculty members. Between September 1999 and April 2000, 3 separate draft versions of this statement were circulated and modified by all members of the participating faculty. Approval of all faculty members was obtained for the final version of the consensus statement, which is organized around broad general principles (Table 1 ) and evidencebased guidelines for neonatal pain management. The pharmacological interventions recommended in these guidelines are not the exclusive products of the pharmaceutical company that funded these meetings, and the representatives of this company have had no input in the format or content of these guidelines. 
Assessment of Pain
• Concomitantly with the vital signs, assessment of neonatal pain must be undertaken and documented every 4 to 6 hours or as indicated by the pain scores or clinical condition of the neonate. [21] [22] [23] [24] • Standardized pain assessment methods with evidence of validity, reliability, and clinical utility should be used [25] [26] [27] [28] [29] [30] [31] [32] (Table 3) . • Pain assessment instruments should be sensitive and specific for infants of different gestational ages and/or with acute, recurrent, or continuous pain. 13, 32, 33 Examples of ongoing, continuous pain may include postoperative pain or inflammatory conditions. 1,3,33 • Pain assessment should be comprehensive and multidimensional, including contextual, behavioral, and physiological indicators. 8, 13, [21] [22] [23] • Pain assessment must be performed after each potentially painful clinical intervention and to evaluate the efficacy of behavioral, environmental, and pharmacological agents. 21, 23, 33, 34 
Management of Pain in the Newborn
• Strategies for prevention, particularly by avoiding recurrent painful stimuli. 20 (Table 4 ). • Pharmacological therapy for ongoing pain 17, 19, 34, 58, [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] ( Table 4 ). 12%-24% solution given orally 2 min before the procedure, 2 mL for term neonates and 0.1-0.4 mL for preterm neonates *It is advised that neonatal intensive care units use only 1 opioid analgesic agent to ensure familiarity with its use. The opioid doses noted are only applicable for opioid-naive patients. All patients receiving analgesic or anesthetic agents should be monitored and carefully observed, particularly if they are breathing spontaneously.
†EMLA indicates eutectic mixture of local anesthetics (lidocaine and prilocaine hydrochloride in an emulsion base). ‡Maximum daily dose: preterm infants (28-32 wk) = 40 mg/kg; preterm infants (32-36 wk) and term infants (Ͻ10 d) = 60 mg/kg; term infants (Ն10 d) = 90 mg/kg.
SUGGESTED MANAGEMENT APPROACHES FOR NEONATAL PAIN
In the following sections, an asterisk indicates that evidence from studies in neonates is available to support the proposed intervention. The combined use of multiple interventions may have additive or synergistic clinical effects.
Heel Lance
• Consider use of venipuncture instead of heel lance in full-term neonates and more mature preterm neonates* (because it is less painful, more efficient and requires less resampling). 62, [81] [82] [83] [84] [85] [86] [87] This approach may not apply to the care of extremely preterm infants. • Use a pacifier* with sucrose* (concentration 12%-24%) given 2 minutes before the procedure. 39 EMLA (a eutectic mixture of local anesthetics: lidocaine and prilocaine hydrochloride in an emulsion base), acetaminophen, and warming the heel are ineffective for heel lancing*; squeezing for blood collection is the most painful part of the procedure. 70 
Percutaneous Arterial Catheter Insertion
• Use a pacifier* with sucrose. 39, 41 • Use swaddling, containment, or facilitated tucking. 37, 38 • Apply EMLA to the proposed site. 60, 70 • Consider subcutaneous infiltration of lidocaine. 58, 70 • Consider a similar approach for arterial puncture.
Peripheral Arterial or Venous Cutdown
• Use a pacifier with sucrose. 39, 41 • Use swaddling, containment, or facilitated tucking. 37 
Central Venous Line Placement
• Use a pacifier* with sucrose. 39, 41 • Use swaddling, containment, or facilitated tucking. 37, 38 • Apply EMLA to the proposed site, if nonurgent. 60, 90 • Consider subcutaneous infiltration of lidocaine. 58, 70 • Consider slow intravenous opioid infusion (morphine sulfate* or fentanyl citrate*). 73, 76 • Consider using general anesthesia for the procedure. 15, 70, 76, 91 Umbilical Catheter Insertion (Umbilical Arterial/Umbilical Venous)
• Consider the use of a pacifier with sucrose. 39, 41 • Use swaddling, containment, or facilitated tucking. 37, 38 • Avoid the placement of sutures or hemostat clamps on the skin around the umbilicus.
Peripherally Inserted Central Catheter Placement
• Use a pacifier with sucrose. 39, 41 • Use swaddling, containment, or facilitated tucking. 37, 38 • Apply EMLA* to the proposed site (when nonurgent). 58, 60, 90 • Consider opioid dose(s), if intravenous access is available. 58, 76, 91 Lumbar Puncture
• Use a pacifier* with sucrose. 39, 41 • Apply EMLA to the proposed site. 60 • Consider subcutaneous infiltration of lidocaine. 58, 70 • Because containment is not possible, careful physical handling is advised.
Subcutaneous or Intramuscular Injection
• Avoid subcutaneous and intramuscular injections; give drugs intravenously whenever possible. If necessary: • Use a pacifier with sucrose. 39, 41 • Use swaddling, containment, or facilitated tucking. 37, 38 • Apply EMLA to the proposed site (evidence for this approach is available from studies in children, but not from studies in neonates). [92] [93] [94] 
Endotracheal Intubation
Many variations in clinical approach have been noted; the superior efficacy of any one technique is not supported by current evidence 33 Tracheal intubation without the use of analgesia or sedation should be performed only for resuscitation in the delivery room or for other life-threatening situations associated with the unavailability of intravenous access. [95] [96] [97] 
Endotracheal Suction
This is considered a stressful procedure and may be associated with the same physiological responses that accompany other painful procedures 71,100-104 :
• Use a pacifier; may consider giving sucrose. 39, 41 • Use swaddling, containment, or facilitated tucking. 37, 38 • Consider continuous intravenous infusion of opioids (morphine*) 71 or slow injection of intermittent opioid doses (fentanyl,* meperidine,* or alfentanil*). [100] [101] [102] [103] [104] 
Nasogastric or Orogastric Tube Insertion
• Use a pacifier with sucrose. 39, 41 • Use swaddling, containment, or facilitated tucking. 37, 38 • Use a gentle technique and appropriate lubrication. 105 
Chest Tube Insertion
• Anticipate the need for intubation and ventilation in neonates breathing spontaneously. 58 • Use a pacifier with sucrose. 39, 41 • Consider subcutaneous infiltration of lidocaine. 58, 70 • Consider slow intravenous opioid infusion (morphine or fentanyl; see Table 4 for dosages). 15, 58 • Other approaches may include the use of shortacting anesthetic agents. 15, 58, 76 The use of intravenous midazolam is not recommended. 106, 107 Circumcision
If deemed necessary 108,109 :
• Use an appropriate clamp (Mogen clamp preferred over Gomco*). 110, 111 • Apply EMLA* to the proposed site. 57, 60, 111 • Place a dorsal penile nerve block,* 64, 111, 112 ring block,* 65, 66 or caudal block, 67, 68, [113] [114] [115] [116] using plain or buffered lidocaine.* 117-119 • Use a pacifier* with sucrose.* 39, 41, 56, 111, 118 • Consider acetaminophen for postoperative pain.* 69 Analgesics can be combined for maximum efficacy, 67, 110, 111, 118 although the addition of sodium bicarbonate to lidocaine does not alter the neonatal responses to lidocaine injection. [117] [118] [119] Ongoing Analgesia for Routine NICU Care and Procedures
• Use swaddling, containment, or facilitated tucking. 37 ,38 • Use a pacifier; may consider giving sucrose. 39, 41 • Low-dose continuous infusion of morphine* or fentanyl* if patient is ventilated. [71] [72] [73] [74] [75] There is no evidence to show that neonates can be safely sedated for several weeks or months 20, 71, 72, 74, 75 and the use of midazolam is not recommended. 71, 106, 107 • Consider acetaminophen therapy.
The efficacy and safety of repeated acetaminophen doses is unknown, rectal absorption is variable, and intravenous propacetamol is not available in the United States. [77] [78] [79] [80] 87 • Reduce acoustic, thermal, and other environmental stresses. 33, 35, 36 COMMENT Recognition of the clinical importance of neonatal pain and stress has been delayed 5,20 by outdated professional attitudes (that newborns are less sensitive to pain), [120] [121] [122] [123] [124] [125] [126] lack of education, 127,128 need for accurate assessment methods, and lack of evidence for the safety and efficacy of management approaches that can be applied to the routine care of neonates. This is a preliminary attempt to present the available evidence so that it may be useful to the clinicians at the bedside. We hope to stimulate further research by clearly outlining the areas where current evidence is not available for defining the efficacy of specific therapeutic approaches. Although these management approaches are mainly applicable for established NICUs that provide advanced medical and nursing care for critically ill neonates, they can be adapted for management of neonatal pain in other clinical settings or geographical locations. Adverse effects that may result from these therapies are listed in Table 5 , and all clinicians using these guidelines must be familiar with the safe use of an- algesic agents in healthy or critically ill, term and preterm neonates. Professionals working with neonates are expected to be knowledgeable about the current assessment and management approaches through participation in ongoing pain education, interaction with pain experts, attention to the most recent research evidence, and adherence to professional standards and clinical guidelines. 159 We strongly support the initiative taken by national professional organizations for the prevention and management of neonatal pain 20, 108, 109 and for the development of standards for health care professionals and institutions. This consensus statement provides evidencebased protocols for developing neonatal pain management guidelines that can be uniquely designed for various clinical situations and diverse practice settings. Adherence to such guidelines will not only improve the clinical care provided to all neonates, but may also have a positive impact on their subsequent health and behaviors during childhood and adolescence. 160 Accepted for publication October 16, 2000. These efforts were supported by an unrestricted educational grant from Astra Pharmaceuticals (now AstraZeneca Inc, London, England) and were developed at 2 meetings of the International Evidence-Based Group for Neonatal Pain (Nice, France, April 21-23, 1998 , and Baden, Austria, August 20-22, 1999 
